A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

NCT05076097 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Orelabrutinib in in combination of rituximab and lenalidomide(OLR)

Sponsor

Tianjin Medical University Cancer Institute and Hospital